Выпуск
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
Pharmaceutical Executive · 23 октября 2026 г. · 2 мин
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.